secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0000950170-22-016850
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon Q2 net loss $9.2M; advances tegoprubart trials across kidney, IgAN, ALS
------------------------------------------------------------------------------

- Net loss of $9.2M ($0.65 per share) vs $7.4M loss in Q2 2021.
- Cash at $70.5M; management expects to fund operations into 2024.
- FDA cleared IND for Phase 2 kidney transplant trial; first patient dosed in Phase 1b ex-US kidney study.
- Positive Phase 2a ALS topline: tegoprubart met safety endpoints; showed target engagement and biomarker reduction.
- Orphan Drug Designation granted for tegoprubart in islet cell transplantation; IgAN trial enrollment ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000095017022016850/0000950170-22-016850-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000095017022016850/eldn-20220811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016850

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer